Logo

Innodem Neurosciences’ ETNA Device Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Sclerosis

Share this

Innodem Neurosciences’ ETNA Device Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Sclerosis

Shots:

  • The US FDA has granted BDD to eye-tracking neurological assessment (ETNA device) for MS. The device is designed to track MS patients' eye movements to estimate disease severity & help clinicians to track disease progression
  • Innodem's patented mobile software technology is embodied in an intuitive application to transform an off-the-shelf electronic tablet into a polyvalent & precise device capturing EMBs & GMBs in minutes, remotely informing clinicians about MS disease & progression to improve patient outcomes
  • Innodem is conducting a clinical trial to demonstrate that new digital EMBs and GMBs may correctly and cost-effectively monitor improvements in MS patients' quality of treatment and QoL

Ref: Innodem | Image: Innodem

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions